FrancophonIA/ELRC3.0 huggingface dataset:
English: • Warning message for patients on the importance of consulting their doctor immediately in case they develop any of the listed signs and symptoms and on the important not attempting to treat themselves.
Croatian: • Poruka s upozorenjem za bolesnike da je važno odmah potražiti savjet liječnika u slučaju da razviju bilo koji od navedenih znakova i simptoma te da ne pokušavaju liječiti sami sebe.
English: It is important that you also read the package leaflet for the medicine containing axitinib.
Croatian: Važno je da pročitate i uputu o lijeku za lijeka koji sadrži aksitinib.
English: Avelumab is primarily metabolised through catabolic pathways, therefore, it is not expected that avelumab will have pharmacokinetic drug-drug interactions with other medicinal products.
Croatian: Avelumab se primarno metabolizira kataboličkim putevima pa se stoga ne očekuje ulazak avelumaba u farmakokinetičke interakcije s drugim lijekovima.
English: • Requirement for 10 mg per day or greater prednisone or equivalent for more than 12 weeks
Croatian: • Potreba za prednizonom u dozi od 10 mg na dan ili višoj ili ekvivalentnim lijekom tijekom više od 12 tjedana
English: Confirmed objective response rate (ORR)
Croatian: Potvrđena stopa objektivnog odgovora (ORR)
English: The elimination half-life (t½) at the recommended dose is 6.1 days based on the population PK analysis.
Croatian: Poluvijek eliminacije (t½) pri preporučenoj dozi iznosi 6,1 dan na temelju populacijske farmakokinetike.
English: Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Croatian: Učestalosti se definiraju kao: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i < 1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000).
English: • Reminder of the importance to consult their doctor before any change of treatment or in case of side effect
Croatian: • Podsjetnik da je važno da potraže savjet liječnika prije ikakve promjene liječenja ili u slučaju nuspojave
English: No studies have been conducted to assess the potential of avelumab for carcinogenicity or genotoxicity.
Croatian: Nisu provedena ispitivanja kojima bi se procijenili kancerogeni potencijal ili genotoksičnost avelumaba.
English: Bavencio binds to PD-L1, and blocks this protective effect, allowing the immune system to attack the tumour cells.
Croatian: Bavencio se veže za PD-L1 i blokira taj zaštitni učinak, što imunološkom sustavu omogućuje da napada tumorske stanice.
English: Randomization was stratified according to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 vs. 1) and region (United States vs. Canada/Western Europe vs. the rest of the world).
Croatian: Eastern Cooperative Oncology Group, ECOG) (0 naspram 1) i regiji (Sjedinjene Američke Države naspram Kanade / zapadne Europe naspram ostatka svijeta).
English: Inflammation may cause serious damage to your body and some inflammatory conditions may lead to death and need treatment or withdrawal of Bavencio.
Croatian: Upala može ozbiljno naškoditi Vašem tijelu, a neka upalna stanja mogu dovesti do smrti te zahtijevati liječenje ili obustavu primjene lijeka Bavencio.
English: Neuropathy peripheral
Croatian: Često periferna neuropatija
English: Pharmacotherapeutic group: Other antineoplastic agents, monoclonal antibodies, ATC code: L01XC31.
Croatian: Farmakoterapijska skupina: drugi antineoplastici, monoklonska protutijela, ATK oznaka: L01XC31.
English: Patients with radiological disease progression not associated with significant clinical deterioration, defined as no new or worsening symptoms, no change in performance status for greater than two weeks, and no need for salvage therapy could continue treatment.
Croatian: Bolesnici s radiološkom progresijom bolesti koja nije povezana sa značajnim kliničkim pogoršanjem, definiranim kao stanje bez pojave novih ili pogoršanja postojećih simptoma, bez promjene općeg stanja dulje od dva tjedna te bez potrebe za drugom linijom terapije, mogli su nastaviti s liječenjem.
English: Although studies to evaluate the effect of avelumab on fertility have not been conducted, there were no notable effects in the female reproductive organs in monkeys based on 1-month and 3-month repeat-dose toxicity studies (see section 5.3).
Croatian: Iako nisu provedena ispitivanja kojima bi se procijenio učinak avelumaba na plodnost, nije bilo primjetnih učinaka na reproduktivne organe ženki majmuna na temelju 1-mjesečnog i 3-mjesečnog ispitivanja toksičnosti ponovljenih doza (vidjeti dio 5.3).
English: For Bavencio in combination with axitinib, see below.
Croatian: Za Bavencio u kombinaciji s aksitinibom vidjeti niže
English: This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses.
Croatian: To sprječava supresivne učinke PD-L1 na citotoksične CD8+ T-stanice, što dovodi do obnove antitumorskih odgovora T-stanica.
English: The MAH shall ensure that in each Member State where Bavencio is marketed, all patients/carers who are expected to use Bavencio have access to/are provided with the following educational package:
Croatian: U svakoj zemlji članici u kojoj je Bavencio u prometu, nositelj odobrenja za stavljanje lijeka u promet osigurat će da svi bolesnici/njegovatelji za koje se očekuje da će primjenjivati Bavencio imaju pristup sljedećem edukacijskom paketu ili da im isti bude uručen:
English: After preparation of infusion
Croatian: Nakon pripreme infuzije
English: In the remaining 1.4% (6/439) of patients, infusion-related reactions occurred after the first 4 infusions and all were of Grade 1 or Grade 2.
Croatian: U preostalih su 1,4 % (6/439) bolesnika reakcije povezane s infuzijom nastupile poslije prve 4 infuzije i sve su bile 1. ili 2. stupnja.
English: Patients should be monitored for signs and symptoms of adrenal insufficiency during and after treatment.
Croatian: Bolesnike je potrebno pratiti zbog mogućih znakova i simptoma adrenalne insuficijencije tijekom i nakon liječenja.
English: Efficacy results are presented in Table 7 and Figure 3 based on a data cut-off date of 28 January 2019.
Croatian: Rezultati ispitivanja djelotvornosti prikazani su u tablici 7 i na slici 3 na temelju podataka od 28. siječnja 2019., što je bio datum prestanka prikupljanja podataka.
English: Based on data available, including the low incidence of immunogenicity, the impact of ADA on pharmacokinetics, efficacy and safety is uncertain, while the impact of neutralizing antibodies (nAb) is unknown.
Croatian: Na temelju dostupnih podataka, uključujući nisku incidenciju imunogeničnosti, nije sigurno kakav je utjecaj protutijela na lijek na farmakokinetiku, djelotvornost i sigurnost, a utjecaj neutralizirajućih protutijela nije poznat.
English: Most immune-related adverse reactions with avelumab were reversible and managed with temporary or permanent discontinuation of avelumab, administration of corticosteroids and/or supportive care.
Croatian: Većina imunološki posredovanih nuspojava avelumaba bila je reverzibilna i zbrinuta privremenim ili trajnim prekidom primjene avelumaba, primjenom kortikosteroida i/ili potpornom skrbi.
English: In patients, whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants may be considered.
Croatian: U bolesnika u kojih se imunološki posredovane nuspojave ne mogu kontrolirati primjenom kortikosteroida može se razmotriti primjena drugih sistemskih imunosupresiva.
English: Duration of response (DOR)
Croatian: Trajanje odgovora (DOR)
English: It is unknown if Bavencio passes into your breast milk.
Croatian: Nije poznato prelazi li Bavencio u majčino mlijeko.
English: Elderly No dose adjustment is needed for elderly patients (≥ 65 years) (see sections 5.1 and 5.2).
Croatian: U starijih bolesnika (≥ 65 godina) nije potrebna prilagodba doze (vidjeti dijelove 5.1 i 5.2).
English: • Grade 2 or Grade 3 clinical signs or symptoms of an immune-related adverse reaction not described above.
Croatian: • Klinički znakovi ili simptomi 2. ili 3. stupnja imunološki posredovane nuspojave koja nije opisana gore.
English: Hepatic function abnormal
Croatian: Često abnormalna jetrena funkcija
English: Steady-state exposure was approximately uniform over a wide range of body weights (30 to 204 kg) for body weight normalised dosing.
Croatian: Izloženost u stanju dinamičke ravnoteže bila je približno ujednačena unutar širokog raspona tjelesne težine (od 30 do 204 kg) kod doziranja normaliziranog prema tjelesnoj težini.
English: The median time to response was 6 weeks (range: 6 weeks to 36 weeks) after the first dose of avelumab.
Croatian: Medijan vremena do odgovora iznosio je 6 tjedana (raspon: od 6 tjedana do 36 tjedana) nakon prve doze avelumaba.
English: Additional secondary endpoints included objective response (OR), time to response (TTR) and duration of response (DOR).
Croatian: Dodatne sekundarne mjere ishoda uključivale su objektivni odgovor (engl. objective response, OR), vrijeme do odgovora (engl. time to response, TTR) i trajanje odgovora (engl. duration of response, DOR).
English: Patients should be monitored for elevated serum creatinine prior to and periodically during treatment.
Croatian: Bolesnike je potrebno pratiti zbog mogućeg povišenja kreatinina u serumu prije i povremeno tijekom liječenja.
English: Administration of avelumab and axitinib was permitted beyond RECIST-defined disease progression based on investigator's assessment of the patient's benefit-risk and clinical condition, including performance status, clinical symptoms, adverse events and laboratory data.
Croatian: Primjena avelumaba i aksitiniba bila je dopuštena i nakon progresije bolesti definirane kriterijima RECIST na temelju procjene koristi i rizika za pojedinog bolesnika te njegovog kliničkog stanja od strane ispitivača, uključujući funkcionalni status bolesnika, kliničke simptome, štetne događaje i laboratorijske podatke.
English: Concentrate for solution for infusion (sterile concentrate).
Croatian: Koncentrat za otopinu za infuziju (sterilni koncentrat).
English: Adrenal insufficiency resolved in 1 patient with corticoid treatment at the time of data cut-off.
Croatian: Adrenalna insuficijencija povukla se u 1 bolesnika uz liječenje kortikosteroidima u vrijeme prestanka prikupljanja podataka.
English: What you need to know before you use Bavencio Do not use Bavencio if you are allergic to avelumab or any of the other ingredients of this medicine (listed in section 6).
Croatian: Nemojte primjenjivati Bavencio ako ste alergični na avelumab ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: Avelumab has negligible influence on the ability to drive and use machines.
Croatian: Avelumab zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: The exposure of avelumab increased dose-proportionally in the dose range of 10 mg/kg to 20 mg/kg every 2 weeks.
Croatian: Izloženost avelumabu povećavala se proporcionalno dozi u rasponu doza od 10 mg/kg do 20 mg/kg svaka 2 tjedna.
English: The observed hazard ratio (HR) for OS was 0.80 (95% CI: 0.616, 1.027) for avelumab in combination with axitinib compared to sunitinib.
Croatian: Opaženi omjer hazarda (HR) za OS iznosio je 0,80 (95 % CI: 0,616; 1,027) za avelumab u kombinaciji s aksitinibom u usporedbi sa sunitinibom.
English: Human IgG1 immunoglobulins are known to cross the placental barrier.
Croatian: Poznato je da ljudski IgG1 imunoglobulini prelaze placentalnu barijeru.
English: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 and up to 5 times upper limit of normal (ULN) or total bilirubin greater than 1.5 and up to 3 times ULN
Croatian: Aspartat aminotransferaza (AST) ili alanin aminotransferaza (ALT) više od 3 te do 5 puta iznad gornje granice normale (GGN) ili ukupni bilirubin više od 1,5 te do 3 puta iznad GGN-a
English: If no improvement within 24 hours on corticosteroids, additional immunosuppression (e.g., mycophenolate, infliximab, anti-thymocyte globulin) should be considered.
Croatian: Ako unutar 24 sata od početka terapije kortikosteroidima ne nastupi poboljšanje, potrebno je razmotriti dodatnu imunosupresiju (npr. mikofenolatom, infliksimabom, antitimocitnim globulinom).
English: Oedema peripheral, influenza like illness
Croatian: Često periferni edem, bolest nalik gripi
English: The median duration of response was not estimable (95% CI: 4 months, not estimable) with a minimum of 1.2 months to a maximum of 8.3 months duration.
Croatian: Medijan trajanja odgovora nije se mogao procijeniti (95 % CI: 4 mjeseca, nije se moglo procijeniti) uz trajanje od minimalno 1,2 mjeseca do maksimalno 8,3 mjeseca.
English: Table 1: Guidelines for withholding or discontinuation of Bavencio Treatment-related adverse reaction
Croatian: Tablica 1: Smjernice za odgodu ili prekid primjene lijeka Bavencio Nuspojava povezana s liječenjem
English: Pregnancy There are no or limited data from the use of avelumab in pregnant women.
Croatian: Nema podataka ili su podaci o primjeni avelumaba u trudnica ograničeni.
English: Adverse reactions Infections and infestations
Croatian: Nuspojave Infekcije i infestacije
English: One vial of 10 mL contains 200 mg of avelumab.
Croatian: Jedna bočica od 10 ml sadrži 200 mg avelumaba.
English: • Brief introduction to Bavencio treatment
Croatian: • Kratak uvod u liječenje lijekom Bavencio
English: The recommended dose of avelumab is 800 mg every 2 weeks.
Croatian: Preporučena doza avelumaba je 800 mg svaka 2 tjedna.
English: Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici bočice i kutiji iza oznake „EXP“.
English: ** CIs are derived using the log-log transformation with back transformation to untransformed scale.
Croatian: ** CI su dobiveni log-log transformacijom uz povratnu transformaciju u netransformiranu ljestvicu.
English: • Swelling in the arms, feet or legs • Weight loss, feeling less hungry
Croatian: • oticanje ruku, stopala ili nogu • gubitak na tjelesnoj težini, smanjen osjećaj gladi
English: Three patients were reported to be overdosed with 5% to 10% above the recommended dose of avelumab.
Croatian: U tri je bolesnika zabilježeno predoziranje dozom avelumaba 5 % do 10 % višom od preporučene.
English: • The diluted solution should be mixed by gently inverting the bag in order to avoid foaming or excessive shearing of the solution.
Croatian: • Razrijeđenu otopinu treba promiješati laganim okretanjem vrećice kako bi se izbjeglo stvaranje pjene ili prekomjerno potresanje otopine.
English: Permanently discontinue
Croatian: Trajno prekinuti primjenu
English: Do not breast-feed while receiving Bavencio and for at least 1 month after your last dose.
Croatian: Nemojte dojiti dok primate Bavencio i tijekom najmanje 1 mjeseca nakon zadnje doze.
English: Hypothyroidism should be managed with replacement therapy and hyperthyroidism with anti-thyroid medicinal product, as needed.
Croatian: Hipotireozu treba zbrinuti nadomjesnom terapijom, a hipertireozu antitiroidnim lijekom, po potrebi.
English: Patients should be monitored for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
Croatian: Bolesnike je potrebno pratiti zbog mogućih promjena u funkciji štitne žlijezde (na početku liječenja, povremeno tijekom liječenja te prema indikaciji na temelju kliničke procjene) te zbog mogućih kliničkih znakova i simptoma poremećaja štitne žlijezde.
English: Treatment with avelumab should be resumed when metabolic control is achieved on insulin replacement therapy.
Croatian: Liječenje avelumabom treba nastaviti kad se postigne metabolička kontrola pomoću nadomjesne terapije inzulinom.
English: IHC: Immunohistochemistry; MCV: Merkel cell polyomavirus; ORR: objective response rate a Based on data from patients evaluable for PD-L1 b Based on data from patients evaluable for MCV by immunohistochemistry (IHC)
Croatian: IHC: imunohistokemja; MCV: poliomavirus Merkelovih stanica; ORR: stopa objektivnog odgovora a Na temelju podataka bolesnika koji su se mogli procijeniti na PD-L1 b Na temelju podataka bolesnika koji su se imunohistokemijski (IHC) mogli procijeniti na MCV.
English: Bavencio is compatible with polyethylene, polypropylene, and ethylene vinyl acetate infusion bags, glass bottles, polyvinyl chloride infusion sets and in-line filters with polyethersulfone membranes with pore sizes of 0.2 micrometre.
Croatian: Bavencio je kompatibilan s infuzijskim vrećicama od polietilena, polipropilena i etilen vinil acetata, staklenim bocama, infuzijskim kompletima od polivinil klorida i ugrađenim filtrima s polietersulfonskim membranama i veličinom pora od 0,2 mikrometra.
English: Thyroid disorders (hypothyroidism/hyperthyroidism) Thyroid disorders can occur at any time during treatment (see section 4.8).
Croatian: Poremećaji štitne žlijezde (hipotireoza/hipertireoza) Poremećaji štitne žlijezde mogu nastati bilo kada tijekom liječenja (vidjeti dio 4.8).
English: • Information that avelumab can cause serious side effects during or after treatment, that need to be treated right away and warning message on the importance of being aware of signs and symptoms while receiving avelumab treatment
Croatian: • Preporuku da potraže informacije u uputi o lijeku • Informaciju o tome da avelumab može uzrokovati ozbiljne nuspojave tijekom ili nakon liječenja, koje je potrebno odmah početi liječiti te upozorenje o tome da je važno poznavati znakove i simptome dok primaju terapiju avelumabom
English: From a microbiological point of view, once opened, the medicinal product should be diluted and infused immediately.
Croatian: S mikrobiološkog gledišta lijek nakon otvaranja treba odmah razrijediti i primijeniti infuzijom.
English: • Merkel cell carcinoma (MCC), a rare type of skin cancer, when it is metastatic (has spread to other parts of the body).
Croatian: • karcinoma Merkelovih stanica, rijetke vrste raka kože, nakon što je metastazirao (proširio se na druge dijelove tijela)
English: • The solution should be inspected to ensure it is clear, colourless, and free of visible particles.
Croatian: • Otopinu treba pregledati kako bi se provjerilo je li bistra, bezbojna i da ne sadrži vidljive čestice.
English: Assessment of tumour status was performed at baseline, after randomisation at 6 weeks, then every 6 weeks thereafter up to 18 months after randomisation, and every 12 weeks thereafter until documented confirmed disease progression by BICR.
Croatian: Procjena statusa tumora provedena je na početku, zatim 6 tjedana nakon randomizacije, nakon toga svakih 6 tjedana do 18 mjeseci nakon randomizacije te poslije toga svakih 12 tjedana sve do dokumentirane potvrde progresije bolesti od strane BICR-a.
English: Avelumab plus axitinib
Croatian: Avelumab plus aksitinib
English: Table 3: Adverse reactions in patients treated with avelumab in combination with axitinib in clinical studies B9991002 and B9991003
Croatian: Tablica 3: Nuspojave u bolesnika liječenih avelumabom u kombinaciji s aksitinibom u kliničkim ispitivanjima B9991002 i B9991003
English: • Life threatening or Grade 4 adverse reaction (excluding endocrinopathies controlled with hormone replacement therapy)
Croatian: 4. stupnja (isključujući endokrinopatije kontrolirane hormonskim nadomjesnim liječenjem)
English: • Feeling less hungry, weight loss
Croatian: • smanjen osjećaj gladi, gubitak na tjelesnoj težini
English: In symptomatic patients, obtain gastroenterology consultation and laboratory investigations (including imaging) to ensure the initiation of appropriate measures at an early stage.
Croatian: U simptomatskih bolesnika treba zatražiti savjet gastroenterologa i provesti laboratorijske pretrage (uključujući slikovne pretrage) kako bi se provođenje odgovarajućih mjera započelo u ranoj fazi.
English: Results (N=116)
Croatian: Rezultati (N=116)
English: Any unused medicine or waste material should be disposed of in accordance with local requirements.
Croatian: Neiskorišteni lijek ili otpadni materijal potrebno je zbrinuti sukladno nacionalnim propisima.
English: If the solution is cloudy, discoloured, or contains particulate matters, the vial should be discarded.
Croatian: Ako je otopina zamućena, promijenila boju ili sadrži čestice, bočicu treba baciti.
English: Breast-feeding women should be advised not to breast-feed during treatment and for at least 1 month after the last dose due to the potential for serious adverse reactions in breast-fed infants.
Croatian: Dojiljama treba savjetovati da ne doje tijekom liječenja i najmanje 1 mjesec nakon zadnje doze zbog mogućih ozbiljnih nuspojava u dojenčadi.
English: In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions.
Croatian: U slučaju predoziranja, bolesnike je potrebno pažljivo pratiti zbog mogućih znakova ili simptoma nuspojava.
English: The objective response rate (ORR) was 62.1% (95% CI: 42.3, 79.3) with 4 (14%) of patients reported to have a complete response and 14 (48%) to have a partial response.
Croatian: Stopa objektivnog odgovora (ORR) iznosila je 62,1 % (95 % CI: 42,3; 79,3) s time da je u 4 (14 %) bolesnika zabilježen potpuni odgovor, a u 14 (48 %) djelomičan odgovor.
English: Grade 2 pneumonitis
Croatian: Pneumonitis 2. stupnja
English: The European Medicines Agency has waived the obligation to submit the results of studies with Bavencio in all subsets of the paediatric population for the treatment of Merkel cell carcinoma and renal cell carcinoma (see section 4.2 for information on paediatric use).
Croatian: Pedijatrijska populacija Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Bavencio u svim podskupinama pedijatrijske populacije za liječenje karcinoma Merkelovih stanica i karcinoma bubrežnih stanica (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Patients received avelumab at a dose of 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Croatian: Bolesnici su primali avelumab u dozi od 10 mg/kg svaka 2 tjedna do progresije bolesti ili neprihvatljive toksičnosti.
English: This is very common.
Croatian: Ovo je vrlo često.
English: Other clinically important immune-related adverse reactions were reported in less than 1% of patients: myositis, hypopituitarism, uveitis, and Guillain-Barré syndrome (see section 4.8).
Croatian: Druge klinički važne imunološki posredovane nuspojave bile su zabilježene u manje od 1 % bolesnika: miozitis, hipopituitarizam, uveitis i Guillain-Barréov sindrom (vidjeti dio 4.8).
English: Avelumab has not been studied in patients with severe renal impairment (GFR 15 to 29 mL/min).
Croatian: Avelumab nije ispitan u bolesnika s teškim oštećenjem funkcije bubrega (GFR od 15 do 29 ml/min).
English: Patients who tolerated axitinib 5 mg twice daily without Grade 2 or greater axitinib-related adverse events for 2 consecutive weeks could increase to 7 mg and then subsequently to 10 mg twice daily.
Croatian: U bolesnika koji su podnosili aksitinib u dozi od 5 mg dvaput na dan bez štetnih događaja 2. ili višeg stupnja tijekom 2 uzastopna tjedna, doza se mogla povisiti na 7 mg, a nakon toga na 10 mg dvaput na dan.
English: Median, months (range)
Croatian: medijan, mjeseci (raspon)
English: Stopping your treatment may stop the effect of the medicine.
Croatian: S prestankom liječenja mogu prestati učinici lijeka.
English: In the supplemental analysis, avelumab CL was found to decrease over time: the largest mean maximal reduction (% coefficient of variation [CV%]) from baseline value with different tumour types was approximately 32.1% (CV 36.2%).
Croatian: U dopunskoj se analizi pronašlo da se sistemski klirens avelumaba smanjuje s vremenom: najveća srednja vrijednost maksimalnog smanjenja (% koeficijenta varijacije) od početne vrijednosti kod različitih vrsta tumora iznosila je približno 32,1 % (koeficijent varijacije 36,2 %).